Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 1/20 | 0.49 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.49 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.49 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.43 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3416558 | 1.00 | SLC6A1 (0.49) | SLC6A1SLC6A12SLC6A11PLA2G1BATG4B | |
| SCHEMBL7604766 | 1.00 | SLC6A1 (0.49) | SLC6A1SLC6A12SLC6A11PLA2G1BATG4B | |
| SCHEMBL11254143 | 0.84 | LMNA (0.42) | SLC6A1SLC6A12SLC6A11PLA2G1BATG4B | |
| SCHEMBL11254947 | 0.81 | L3MBTL1 (0.47) | SLC6A1SLC6A12SLC6A11POLBALDH1A1 | |
| Lactic Acid SCHEMBL28394187 | 0.79 | MAPT (0.36) | SLC6A1SLC6A12SLC6A11PLA2G1BATG4B | |
| Lactic Acid SCHEMBL28384632 | 0.79 | MAPT (0.36) | SLC6A1SLC6A12SLC6A11PLA2G1BATG4B | |
| Lactic Acid SCHEMBL28384633 | 0.79 | MAPT (0.36) | SLC6A1SLC6A12SLC6A11PLA2G1BATG4B | |
| SCHEMBL4668723 | 0.77 | NR3C1 (0.43) | SLC6A1SLC6A12SLC6A11PLA2G1BATG4B | |
| SCHEMBL4443441 | 0.77 | NR3C1 (0.43) | SLC6A1SLC6A12SLC6A11PLA2G1BATG4B | |
| SCHEMBL4669632 | 0.77 | NR3C1 (0.43) | SLC6A1SLC6A12SLC6A11PLA2G1BATG4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | Exciva GmbH (DE) | 2022-10-25 | — | — | US | disclosed |
| EP-1937407-B1 | SOLUTIONS OF ANHYDROUS LANTHANIDE SALTS AND ITS PREPARATION | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2015-04-22 | — | — | EP | disclosed |
| EP-1937407-B1 | SOLUTIONS OF ANHYDROUS LANTHANIDE SALTS AND ITS PREPARATION | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2015-04-22 | — | — | EP | disclosed |
| WO-2013118118-A1 | ALPHA-HYDROGEN SUBSTITUTED NITROXYLS AND DERIVATIVES THEREOF AS CATALYSTS | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2013-08-15 | — | — | WO | disclosed |
| US-8470982-B2 | Solutions of anhydrous lanthanide salts and its preparation | LUDWIG-MAXIMILIANS-UNIVERSITAET (DE) | 2013-06-25 | — | — | US | disclosed |
| US-8470982-B2 | Solutions of anhydrous lanthanide salts and its preparation | LUDWIG-MAXIMILIANS-UNIVERSITAET (DE) | 2013-06-25 | — | — | US | disclosed |
| US-8470982-B2 | Solutions of anhydrous lanthanide salts and its preparation | LUDWIG-MAXIMILIANS-UNIVERSITAET (DE) | 2013-06-25 | — | — | US | disclosed |
| US-20090326235-A1 | Solutions of anhydrous lanthanide salts and its preparation | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2009-12-31 | — | — | US | disclosed |
| US-20090326235-A1 | Solutions of anhydrous lanthanide salts and its preparation | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2009-12-31 | — | — | US | disclosed |
| US-20090326235-A1 | Solutions of anhydrous lanthanide salts and its preparation | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2009-12-31 | — | — | US | disclosed |
| EP-1937407-A1 | SOLUTIONS OF ANHYDROUS LANTHANIDE SALTS AND ITS PREPARATION | Ludwig-Maximilians-Universität München (DE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007026014-A1 | SOLUTIONS OF ANHYDROUS LANTHANIDE SALTS AND ITS PREPARATION | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007026014-A1 | SOLUTIONS OF ANHYDROUS LANTHANIDE SALTS AND ITS PREPARATION | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2007-03-08 | — | — | WO | disclosed |
| EP-1759765-A1 | Solutions of anhydrous lanthanide salts and its preparation | Ludwig-Maximilians-Universität München (DE) | 2007-03-07 | — | — | EP | disclosed |
| EP-1759765-A1 | Solutions of anhydrous lanthanide salts and its preparation | Ludwig-Maximilians-Universität München (DE) | 2007-03-07 | — | — | EP | disclosed |
| EP-0973725-B1 | NEW 1,7,7-TRIMETHYL-BICYCLO 2.2.1]HEPTANE DERIVATIVES | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2002-06-19 | — | — | EP | disclosed |
| US-6093747-A | SELECTIVELY BINDING 5-HT2C RECEPTORS IN A MAMMAL | EGIS GYOGYSZERGYAR RT. (HU) | 2000-07-25 | — | — | US | disclosed |
| EP-0973725-A2 | NEW 1,7,7-TRIMETHYL-BICYCLO 2.2.1]HEPTANE DERIVATIVES | EGIS GYOGYSZERGYAR RT. (HU) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998017230-A2 | NEW 1,7,7-TRIMETHYL-BICYCLO[2.2.1]HEPTANE DERIVATIVES | EGIS Gyógyszergyár Rt. (HU) | 1998-04-30 | — | — | WO | disclosed |
| US-4342762-A | USEFUL AS TRANQUILIZERS, ANALGESICS, ANTIEPILEPTIC AGENTS, AND AS A TREATMENT FOR PARKINSON'S DISEASE | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1982-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | HTR2A, HTR2C, CYP3A43 | SLC6A1 507/4885SLC6A12 1460/4885SLC6A11 718/4885 |
| US-20090326235-A1 | Solutions of anhydrous lanthanide salts and its preparation | SLC39A3, AQP3, IKZF3 | SLC6A1 1137/4885SLC6A12 338/4885SLC6A11 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.